Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
5,016
datasets available to search
ShareScore release 0.9.0
Dataset results
5,016 results for “THERAPEUTICS”
Bulk and single-cell gene expression profiling of SARS-CoV-2 infected human cell lines identifies molecular targets for therapeutic intervention
<p>Single cell RNA seq datasets used for analysis in the Bulk and single-cell gene expression profiling of SARS-CoV-2 infected human cell lines identifies molecular targets for therapeutic intervention</p>
Multi-omic Insights into Molecular Mechanism and Therapeutic Targets in Spinocerebellar Ataxia type 7
<p>The molecular mechanism in spinocerebellar ataxia type 7 is currently poorly understood. To provide understandings, a multi-omic study was performed using SCA7266Q/5Q mice. At week 12, entire brain tissue samples were collected and RNA sequencing, methylation analysis, and proteomic analysis were performed. Results were integrated to identify genes with identical trends in expression. Data was also compared with SCA patient serum proteomic analysis, and based on common differentially expressed proteins, a Naïve Bayesian network model was constructed to predict nilotinib treatment response. Data from RNA sequencing and methylation analysis revealed 58 significantly hypomethylated-upregulated genes and 62 hypermethylated-downregulated genes, mostly enriched in GO terms of regulation of axonogenesis, channel activity, and monoamine signaling. In the proteomic analysis, 211 upregulated and 281 downregulated DEPs associated mostly with immune response and cellular mobility were identified. Two genes, Fam107b and Tph2, showed differential expression in both transcriptomic and proteomic analysis. Forty-two overlapping proteins were identified compared with SCA patient serum, and Bayesian network analysis revealed that nilotinib treatment response was associated with the protein expression of CLU, CA2, GLUL, PRDX6, C1QA, PLXNB1, and age. These findings will serve as an important reference for future studies on the pathogenesis and discovery of druggable targets. </p>
Exploring Data Evaluation Strategies for Enhanced Identification of Host Cell Proteins in Drug Products of Therapeutic Antibodies and Fc-Fusion Proteins
<p>This data repository contains all previously unpublished raw data files for the manuscript “Exploring Data Evaluation Strategies for Enhanced Identification of Host Cell Proteins in Drug Products of Therapeutic Antibodies and Fc-Fusion Proteins” by Wolfgang Esser-Skala, Marius Segl, Therese Wohlschlager, Veronika Reisinger, Johann Holzmann, and Christian G. Huber. See <em>readme.md</em> for further information.</p>
Supplementary Figures. "In silico research of new therapeutics rotenoids derivatives against Leishmania amazonensis infection"
<p>Supplementary figures corresponding to the submitted manuscript entitled "In silico research of new therapeutics rotenoids derivatives against Leishmania amazonensis infection"</p>
Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation
<p>Compressed directories containing code and data files sufficient to reproduce analysis from Bloom et al paper on <em>Lactobacillus iners</em> (<em>Nature Microbiology</em>). An earlier, non-peer-reviewed manuscript version containing largely the same analysis was posted as a pre-print in <em>bioRxiv</em> at (https://doi.org/10.1101/2021.06.12.448098). Three compressed directory for analyses of:</p> <ol> <li>Vaginal <em>Lactobacillus </em>genome catalog characterization and gene content analysis.</li> <li>Analysis of relationship between cervicovaginal microbiota composition and cysteine concentrations in vaginal fluid from a South African cohort</li> <li>Analysis of results of <em>in vitro </em>mixed culture competition assays including: <ol> <li>Pairwise competition between <em>L. iners</em> and <em>Lactobacillus crispatus</em> in <em>Lactobacillus</em> MRS broth containing L-cysteine +/- S-methyl-L-cysteine (SMC)</li> <li>Defined bacterial-vaginosis (BV)-like communities including <em>L. iners</em>, <em>L. crispatus</em>, and BV-associated species <em>Gardnerella vaginalis</em>, <em>Prevotella bivia</em>, and <em>Atopobium (Fannyhessea) vaginae</em> cultured in S-broth with or without SMC and/or metronidazole.</li> </ol> </li> </ol>
Data files: Single-cell RNA profiling of Plasmodium vivax-infected hepatocytes reveals parasite- and host- specific transcriptomic signatures and therapeutic targets
<p>Scripts, preprocessed count matrices, and single-cell data objects generated in <strong>“Single-cell RNA profiling of <em>Plasmodium vivax</em><em>-</em>infected hepatocytes reveals parasite- and host- specific transcriptomic signatures and therapeutic targets” </strong></p>
Preparing educational presentation about therapeutic exercises to resident physiatrists
<p>This study evaluated the effectiveness of ChatGPT-4o, a generative artificial intelligence (AI) platform, in preparing educational presentation on therapeutic exercises specifically designed for physiatry residents. Both a physiatry expert and ChatGPT-4 created PowerPoint slides for a presentation on therapeutic exercises using the same reputable sources. Two other physiatry experts, blinded to the origin of the presentation and each other's scores, independently assessed both presentations using four of the CLEAR criteria (completeness, lack of false information, appropriateness, and relevance).</p> <p>Statistical analyses confirmed the interrater reliability. The average scores of the expert-prepared slides were significantly higher than those of the AI-prepared slides. However, when assessing the presentations as a whole, no statistically significant difference emerged between the average AI and expert scores. The overall scores of the AI-prepared slides were rated between good and excellent, while the expert-prepared slides were rated as excellent. Similarly, when assessing the presentations as a whole, the AI performed good whereas expert performed excellent. Upon evaluating the variability within the model for the assessed criteria, it was found that the AI ranked highest in relevance, whereas the expert ranked highest in terms of lack of false information.</p> <p>These findings indicated that although ChatGPT-4o can produce effective educational content, the expert still outperformed AI. This underscores the importance of professional oversight in maintaining the educational quality of resident physician training. Furthermore, fostering collaboration between humans and AI can lead to enhanced educational outcomes in the field.</p>
Data and scripts for SCLC_CellMiner: Integrated Genomics and Therapeutics Predictors of Small Cell Lung Cancer Cell Lines based on their genomic signatures
<p>This is the repository of data and scripts for the analysis of the CellminerCDB-SCLC manuscript and website (<a href="https://discover.nci.nih.gov/SclcCellMinerCDB/">https://discover.nci.nih.gov/SclcCellMinerCDB/</a>)</p> <p> </p> <p>CellMiner-SCLC (https://discover.nci.nih.gov/SclcCellMinerCDB) integrates 118 patient-derived cell lines with drug sensitivity and genomic datasets, including high resolution methylome and RNAseq data. CellMiner-SCLC provides a new resource for SCLC research for this “recalcitrant cancer”. Of fundamental importance, we demonstrate the reproducibility and stability of the cell line datasets from different institutions (CCLE, GDSC, CTRP, NCI and UTSW). We validate the classification based on four master transcription factors: NEUROD1, ASCL1, POU2F3 and YAP1 and show transcription networks connecting them with the MYC genes (MYC, MYCL1 and MYCN) and the NOTCH and HIPPO pathways. We find that the 4 subsets express specific surface markers for antibody-targeted therapies. The YAP1-driven (SCLC-Y) cell lines differ from the other subsets by expressing the NOTCH pathway, epithelial-mesenchymal-transition (EMT) and antigen-presenting machinery (APM) genes, and by responding to mTOR and AKT inhibitors, suggesting the potential of NOTCH modulators, YAP1 inhibitors and immune checkpoint inhibitors for SCLC-Y tumors.</p>
Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq
<p><strong><a href="https://gitlab.com/bu_cnio/Beyondcell">Beyondcell</a> </strong>is a methodology for the identification of drug vulnerabilities in single cell RNA-seq data. To this end, <strong>Beyondcell</strong> focuses on the analysis of drug-related commonalities between cells by classifying them into distinct therapeutic clusters. We have validated the tool in a population of MCF7-AA cells exposed to 500nM of bortezomib and collected at different time points: t0 (before treatment), t12, t48 and t96 (72h treatment followed by drug wash and 24h of recovery) obtained from <a href="https://www.nature.com/articles/s41586-018-0409-3"><strong><em>Ben-David U, et al., Nature, 2018</em></strong></a>. Here, you can find the integrated Seurat object obtained from this analysis. This object is meant to help users follow <strong>Beyondcell's</strong> <a href="https://gitlab.com/bu_cnio/Beyondcell/-/tree/master/tutorial/analysis_workflow">analysis workflow</a>.</p> <p> </p>
Research data supporting "Enzyme Prodrug Therapy Engineered into Electrospun Fibers with Embedded Liposomes for Controlled, Localized Synthesis of Therapeutics"
<p>Research data supporting the publication: Chandrawati R. et al., 2017, Enzyme Prodrug Therapy Engineered into Electrospun Fibers with Embedded Liposomes for Controlled, Localized Synthesis of Therapeutics, Advanced Healthcare Materials. DOI: 10.1002/adhm.201700385</p>
SUPPLEMENTARY (For MD) An integrative pan-genome and subtractive proteomics approach for the identification of potential novel therapeutic drug target against antibiotic resistant honeybee pathogen Paenibacillus larvae
<p><strong>Parameters</strong></p><p>Force field: AMBER ff19SB</p><p>Water type: TIP3P</p><p>Ions: NaCl </p><p>Ligand topology force field: GAFF2</p><p>Temperature: 298k</p><p>Pressure: 1 bar</p><p>minimization step: 20000 on 5 nanoseconds</p><p>initial velocity is changed by changing "ntx" and "ig"</p><p>C2: ntx = 5 , ig = 8</p><p>C3: ntx = 2 , ig = 5</p><p> </p><p><strong>Uploads</strong>- </p><p>1. Zip file of all 3 main files</p><p>2. Unzip file of C1 (Trajectory, PDB complex after each 10 ns run, and Mp4 video of Complex)</p><p>3. Zip file of C1</p><p>4. Unzip file of C2 (Trajectory, PDB complex after each 10 ns run, and Mp4 video of Complex)</p><p>5. Zip file of C2</p><p>6. Unzip file of C3 (Trajectory, PDB complex after each 10 ns run, and Mp4 video of Complex)</p><p>7. Zip file of C3</p><p>8. Zip and unzip file of <strong>Initial</strong> PDB of complex prior to MD simulation with <strong>Post</strong> MD PDB (C1, C2, C3)</p><p>9. Zip file of <strong>topology</strong> files for C1, C2, and C3</p>
Dataset for "Evaluation of Publicly Available Information on Sex-related Differences in the Efficacy and Safety of New Molecular Entities and Therapeutic Biological Products"
<p>Contains our extraction sheets with additional documents/notes on methods used in our study.</p>
ATOPE+Breast, Continuous Monitoring of Training Load in Patients with Breast Cancer during Therapeutic Exercise Intervention
<p>The ATOPE+Breast dataset (ATOPE+ for patients with breast cancer) describes the daily status of 23 patients with breast cancer during therapeutic exercise intervention with daily measures of HRV, self-reported wellness, physical activity, and sleep. Besides, the ATOPE+Breast dataset contains information about training sessions, such as intensity recorded, demographic data, treatment details, initial evaluations of quality of life, physical activity levels, previous medical conditions, and risk factors. ATOPE+Breast was recorded using the ATOPE+ mHealth system, whose usability [1] and reliability [2] were successfully validated.</p> <p>References</p> <ul> <li>[1] S. Moreno-Gutierrez et al., “ATOPE+: An mHealth System to Support Personalized Therapeutic Exercise Interventions in Patients With Cancer,” IEEE Access, vol. 9, pp. 16878–16898, 2021, doi: 10.1109/ACCESS.2021.3049398.</li> <li>[2] P. Postigo-Martin et al., “mHealth system (ATOPE+) to support exercise prescription in breast cancer survivors: A validity and reliability, cross-sectional observational study (ATOPE study) (Preprint),” JMIR mHealth and uHealth, Preprint, Jan. 2022. doi: 10.2196/preprints.36733.</li> </ul>
Global Functional Genomics Reveals GRK5 as a Therapeutic Target for Cystic Fibrosis
<p>Cystic Fibrosis (CF) is a life-shortening disease affecting >90,000 individuals worldwide predominantly with respiratory symptoms. About 80% of individuals with CF have the F508del mutation that causes the CF transmembrane conductance regulator (CFTR) protein to misfold and be targeted for premature degradation by the endoplasmic reticulum (ER) quality control (ERQC), thus preventing its plasma membrane (PM) traffic. Despite the recent approval of a ‘highly effective’ drug rescuing F508del-CFTR, maximal lung function improvement is ~14% and the drug-targeted genes remain unknown.</p> <p>To identify global modulators of F508del traffic, we performed a high-content siRNA microscopy-based screen of >9,000 genes and monitored F508del-CFTR PM rescue in human airway cells. This primary screen identified 227 F508del-CFTR traffic regulators, of which 35 could be validated by additional siRNAs. Subsequent mechanistic studies established GRK5 as a robust regulator whose inhibition rescues F508del-CFTR PM traffic, thus emerging as a novel potential drug target for CF.</p>
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations
<p>This study aims to investigate the accumulation of genomic instability and chromosome segregation errors after the acquisition of resistance to CDK4/6i in ER+ breast cancer and to test the efficacy of mitotic kinase inhibitors as a potential treatment for CDK4/6i-resistant breast cancer patients.</p> <p><strong>This repository contains whole-exome and shallow whole-genome sequencing from luminal breast cancer cell lines (T47D, LY2, MDA-MB-361, CAMA1, MCF7, KPL1, ZR751, HCC1428) both at the untreated or Parental state and post resistance to Palbociclib.</strong></p> <p>Palbociclib resistance was developed by continuous dose-escalation of palbociclib up to 0.5-1 μM until cell growth was observed in the presence of the drug (6-8 months for cell lines). During this time, parental cell lines and organoids were cultured in regular media to match the time spent in culture. Once resistance was established, Palbo-R cell lines were cultured in a regular growth medium without palbociclib. Cells were cultured without palbociclib for at least two weeks before evaluating resistance.</p>
Dataset: Achilles Therapeutics plc (ACHL) Stock Performance
This dataset provides historical stock market performance data for specific companies. It enables users to analyze and understand the past trends and fluctuations in stock prices over time. This information can be utilized for various purposes such as investment analysis, financial research, and market trend forecasting.
Dataset: Abeona Therapeutics Inc. (ABEO) Stock Performance
This dataset provides historical stock market performance data for specific companies. It enables users to analyze and understand the past trends and fluctuations in stock prices over time. This information can be utilized for various purposes such as investment analysis, financial research, and market trend forecasting.
Dataset: Halozyme Therapeutics, Inc. (HALO) Stock Performance
This dataset provides historical stock market performance data for specific companies. It enables users to analyze and understand the past trends and fluctuations in stock prices over time. This information can be utilized for various purposes such as investment analysis, financial research, and market trend forecasting.
Dataset: Gyre Therapeutics, Inc. (GYRE) Stock Performance
This dataset provides historical stock market performance data for specific companies. It enables users to analyze and understand the past trends and fluctuations in stock prices over time. This information can be utilized for various purposes such as investment analysis, financial research, and market trend forecasting.
Dataset: G1 Therapeutics, Inc. (GTHX) Stock Performance
This dataset provides historical stock market performance data for specific companies. It enables users to analyze and understand the past trends and fluctuations in stock prices over time. This information can be utilized for various purposes such as investment analysis, financial research, and market trend forecasting.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.